Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Carcinoma, Pancreatic Ductal*/genetics ; Carcinoma, Pancreatic Ductal*/immunology ; Carcinoma, Pancreatic Ductal*/pathology ; Carcinoma, Pancreatic Ductal*/metabolism ; Pancreatic Neoplasms*/genetics ; Pancreatic Neoplasms*/immunology ; Pancreatic Neoplasms*/pathology ; Pancreatic Neoplasms*/metabolism ; Pancreatic Intraductal Neoplasms*/genetics ; Pancreatic Intraductal Neoplasms*/metabolism ; Pancreatic Intraductal Neoplasms*/pathology; Humans ; Male ; Female ; Gene Expression Regulation, Neoplastic ; Biomarkers, Tumor/genetics ; Tumor Microenvironment/immunology ; Tumor Microenvironment/genetics ; Middle Aged ; Aged ; Gene Expression Profiling ; Transcriptome ; Signal Transduction

Intraductal papillary mucinous neoplasms (IPMN) are commonly detected pancreatic cysts that may transform into pancreatic ductal adenocarcinoma (PDAC). Predicting which IPMNs will progress to PDAC remains a clinical challenge. Moreover, identifying those clinically evident IPMNs for which a surveillance approach is best is a dire clinical need. Therefore, we aimed to identify molecular signatures that distinguished between PDAC with and without clinical evidence of an IPMN to identify novel molecular pathways related to IPMN-derived PDAC that could help guide biomarker development. Data from the Oncology Research Information Exchange Network (ORIEN) multi-institute sequencing project were utilized to analyze 66 PDAC cases from Moffitt Cancer Center and The Ohio State University Wexner Medical Center, for which tumor whole transcriptome sequencing datasets were generated. Cases were classified based on whether a tumor had originated from an IPMN ( n = 16) or presumably through the pancreatic intraepithelial neoplasia (PanIN) pathway ( n = 50). We then performed differential expression and pathway analysis using Gene-Set Enrichment Analysis (GSEA) and Pathway Analysis with Down-weighted Genes (PADOG) algorithms. We also analyzed immune profiles using the Tumor-Immune Microenvironment Deconvolution web portal for Bulk Transcriptomics (TIMEx). Both GSEA and TIMEx indicate that PanIN-derived PDAC tumors enrich inflammatory pathways (complement, hedgehog signaling, coagulation, inflammatory response, apical surface, IL-2/STAT5, IL-6/STAT3, EMT, KRAS signaling, apical junction, IFN-gamma, allograft rejection) and are comparatively richer in almost all immune cell types than those from IPMN-derived PDAC. IPMN-derived tumors were enriched for metabolic and energy-generating pathways (oxidative phosphorylation, unfolded protein response, pancreas beta cells, adipogenesis, fatty acid metabolism, protein secretion), and the most significantly upregulated genes (padj < 0.001) included mucin 2 (MUC2) and gastrokine-2 (GKN2). Further, the metabolic-linked gene signature enriched in the IPMN-derived samples is associated with a cluster of early-stage and long-survival (top 4th quartile) PDAC cases from The Cancer Genome Atlas (TCGA) expression database. Our data suggest that IPMN-derived and PanIN-derived PDACs differ in the expression of immune profiles and metabolic pathways. These initial findings warrant validation and follow-up to develop biomarker-based strategies for early PDAC detection and treatment.

1R37CA229810-21A1 United States NH NIH HHS; NOVA ORIEN New Oncology Visionary Award

Keywords: IPMN; PanIN; pancreatic ductal adenocarcinoma; transcriptomics

0 (Biomarkers, Tumor)

Date Created: 20241217 Date Completed: 20241217 Latest Revision: 20241217

20241217

10.3390/ijms252313164

39684873